340 related articles for article (PubMed ID: 23565717)
21. 2 new drugs for weight loss.
Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
[No Abstract] [Full Text] [Related]
22. Phentermine plus topiramate in the treatment of obesity.
Malgarini RB; Pimpinella G
Lancet; 2011 Jul; 378(9786):125-6; author reply 126-7. PubMed ID: 21742167
[No Abstract] [Full Text] [Related]
23. ACS chemical neuroscience molecule spotlight on Qnexa.
Mercer SL
ACS Chem Neurosci; 2011 Apr; 2(4):183-4. PubMed ID: 22778866
[TBL] [Abstract][Full Text] [Related]
24. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Woloshin S; Schwartz LM
JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
[TBL] [Abstract][Full Text] [Related]
25. Drug treatment of obesity in the cardiovascular patient.
Charakida M; Tousoulis D; Finer N
Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
[TBL] [Abstract][Full Text] [Related]
26. The FDA's assessment of two drugs for chronic weight management.
Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C
N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510
[No Abstract] [Full Text] [Related]
27. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
Garvey WT
Expert Opin Drug Saf; 2013 Sep; 12(5):741-56. PubMed ID: 23738843
[TBL] [Abstract][Full Text] [Related]
28. Two anti-obesity hopefuls and their safety.
Bello NT; Campbell SC
Expert Opin Drug Saf; 2012 Sep; 11(5):681-3. PubMed ID: 22788876
[No Abstract] [Full Text] [Related]
29. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness Analysis of Qsymia for Weight Loss.
Finkelstein EA; Kruger E; Karnawat S
Pharmacoeconomics; 2015 Jul; 33(7):699-706. PubMed ID: 24986038
[TBL] [Abstract][Full Text] [Related]
31. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
[TBL] [Abstract][Full Text] [Related]
33. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
Davidson MH; Tonstad S; Oparil S; Schwiers M; Day WW; Bowden CH
Am J Cardiol; 2013 Apr; 111(8):1131-8. PubMed ID: 23375187
[TBL] [Abstract][Full Text] [Related]
34. Obesity Epidemic: Pharmaceutical Weight Loss.
Curry SA
R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
[TBL] [Abstract][Full Text] [Related]
35. Recent advancements in drug treatment of obesity.
Carter R; Mouralidarane A; Ray S; Soeda J; Oben J
Clin Med (Lond); 2012 Oct; 12(5):456-60. PubMed ID: 23101148
[TBL] [Abstract][Full Text] [Related]
36. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
37. Phentermine/topiramate for the treatment of obesity.
Smith SM; Meyer M; Trinkley KE
Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
[TBL] [Abstract][Full Text] [Related]
38. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
39. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
Allison DB; Gadde KM; Garvey WT; Peterson CA; Schwiers ML; Najarian T; Tam PY; Troupin B; Day WW
Obesity (Silver Spring); 2012 Feb; 20(2):330-42. PubMed ID: 22051941
[TBL] [Abstract][Full Text] [Related]
40. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.
Acosta A; Camilleri M; Shin A; Vazquez-Roque MI; Iturrino J; Burton D; O'Neill J; Eckert D; Zinsmeister AR
Gastroenterology; 2015 Mar; 148(3):537-546.e4. PubMed ID: 25486131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
